Some IBS Treatments May Be Linked to Slightly Higher Risk of Early Death
Recent research has raised concerns about the long-term use of certain medications for irritable bowel syndrome (IBS) and their potential association with an increased risk of early mortality. While the findings suggest a link, experts emphasize that the overall risk remains low and that the benefits of medication may significantly outweigh these concerns.
A study conducted by researchers at Cedars-Sinai Health Sciences University in Los Angeles analyzed health records from nearly 670,000 adults over two decades. The researchers found that long-term use of two specific medications—loperamide and diphenoxylate—was linked to approximately double the risk of death. Additionally, using antidepressants to manage IBS symptoms was associated with a 35% elevated risk of mortality.
Despite these findings, Dr. Ali Rezaie, the study’s senior author and medical director of the GI Motility Program at Cedars-Sinai, reassured patients not to panic. “The risk to any individual is small,” he commented. Nonetheless, he acknowledged the importance of understanding these potential risks, especially for patients who may require long-term treatment.
The study, published in Communications Medicine, highlights a significant gap in knowledge regarding the long-term safety of IBS treatments, as most clinical trials have been limited to less than a year in duration. “Many patients are diagnosed at a young age and may remain on medications for years,” Rezaie noted.
Gastroenterologist Dr. Rudolph Bedford, who was not involved in the study, reinforced that while the findings indicate an association rather than a direct cause-and-effect relationship, the symptoms of IBS can be debilitating. He argued that the advantages of medication often outweigh the risks. “At the end of the day, it’s about quality of life,” he said.
Researchers also clarified that their study does not imply that these medications directly cause death. Instead, they suggest that increased risks of adverse health outcomes, such as cardiovascular issues, may contribute to the observed associations. Other IBS treatments, including antispasmodics and certain constipation medications, did not exhibit a similar increase in mortality risk.
Experts advise those with IBS to discuss their treatment options with healthcare providers, especially if they have other risk factors that could influence their health outcomes. Dr. Ketan Thanki, a colorectal surgeon, emphasized the need for continued research to better understand these findings, while also encouraging patients to remain informed but not alarmed.
IBS affects an estimated 25 to 45 million people in the United States, with symptoms ranging from mild to severe. Management strategies include dietary modifications, regular exercise, stress reduction, and, when necessary, medications. For many, a combination of lifestyle changes and medication can effectively alleviate symptoms and improve quality of life.
